Table 1.
OR of baseline clinical characteristics for dalfampridine responders.
| PR | FR | OR | 95% CI | p | |
|---|---|---|---|---|---|
| n = 37 | n = 34 | ||||
| Gender, n (%) | |||||
| Male | 19 (51.4) | 11 (32.4) | 1 | ||
| Female | 18 (48.7) | 23 (67.7) | 2.21 | 0.8–5.8 | 0.108 |
| Age years, mean (SD) | 49.0 (8.2) | 48.1 (7.2) | 1.00 | 0.9–1.1 | 0.924 |
| Formal education, mean (SD) | 13.1 (3.5) | 12.5 (3.5) | 0.95 | 0.8–1.1 | 0.477 |
| Phenotypes, n (%) | |||||
| Relapsing remitting | 34 (91.9) | 29 (85.3) | 1 | ||
| Secondary progressive | 3 (8.1) | 4 (11.8) | 1.56 | 0.3–7.6 | 0.579 |
| Primary progressive | 0 (0.0) | 1 (2.9) | |||
| Patients under DMT, n (%) | |||||
| No | 13 (35.1) | 13 (38.2) | 1 | ||
| Yes | 24 (62.2) | 21 (61.8) | 0.91 | 0.3–2.4 | 0.854 |
| Disease duration, years, mean (SD) | 15.2 (8.0) | 12.5 (9.0) | 0.96 | 0.9–1.0 | 0.179 |
| EDSS, median (range) | 4 (3–5) | 3 (1.5–4.5) | 0.69 | 0.5–0.97 | 0.034 |
p values refer to univariate logistic regression.
CI, confidence interval; DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; FR, fully responders; OR, odds ratio; PR, partially responders.